Converting a Breakthrough Modality into an Operationally Reliable Discovery Platform

Session details:

• The structural challenges that prevent many new modalities from scaling beyond their first asset and how to design around them
• How to move with urgency while avoiding industry hype cycles
• Why intentional target selection is critical when pursuing difficult biology such as historically undrugged transcription factors in immunology
• How evolving biochemical and computational capabilities magnify insights for optimized oral medicines